| Members |
acceptabilityId |
| % chlorure de sodium |
Preferred (foundation metadata concept) |
| 'bubble' gastrique |
Acceptable (foundation metadata concept) |
| 'shaving' |
Preferred (foundation metadata concept) |
| 'shaving' de la patella |
Preferred (foundation metadata concept) |
| 'shaving' endoscopique d'un cartilage articulaire |
Preferred (foundation metadata concept) |
| 'strapping' d'un pied bot |
Preferred (foundation metadata concept) |
| 'strapping' patellaire |
Preferred (foundation metadata concept) |
| 'stress test' articulaire négatif |
Preferred (foundation metadata concept) |
| 'stress test' articulaire positif |
Preferred (foundation metadata concept) |
| 'stress test' cervical négatif |
Preferred (foundation metadata concept) |
| 'stress test' cervical positif |
Preferred (foundation metadata concept) |
| 'stripping' |
Preferred (foundation metadata concept) |
| 'stripping' d'un os |
Preferred (foundation metadata concept) |
| 'stripping' d'une veine saphène variqueuse |
Preferred (foundation metadata concept) |
| 'stripping' de l'enthèse calcanéenne d'un muscle intrinsèque du pied |
Preferred (foundation metadata concept) |
| 'stripping' de la grande veine saphène |
Preferred (foundation metadata concept) |
| 'stripping' de la petite veine saphène |
Preferred (foundation metadata concept) |
| 'stripping' et ligature de la grande veine saphène |
Preferred (foundation metadata concept) |
| 'stripping' et ligature veineuse de la jambe |
Preferred (foundation metadata concept) |
| 'stripping' et ligature veineuse du membre inférieur |
Preferred (foundation metadata concept) |
| 'stripping' veineux |
Preferred (foundation metadata concept) |
| 'stroke test' du genou |
Preferred (foundation metadata concept) |
| (s)- tricyclamol |
Preferred (foundation metadata concept) |
| 0,5 |
Preferred (foundation metadata concept) |
| 0,5 mL de poudre en flacon du vaccin vivant contre la rubéole |
Preferred (foundation metadata concept) |
| 0215 x 028 |
Preferred (foundation metadata concept) |
| 1,1,1,2-tétrachloro 2,2-difluoroéthane |
Preferred (foundation metadata concept) |
| 1,1,1-trichloroéthane |
Preferred (foundation metadata concept) |
| 1,1,2,2-tétrachloro 1,2-difluoroéthane |
Preferred (foundation metadata concept) |
| 1,1-dichlorobutane |
Preferred (foundation metadata concept) |
| 1,2-dichloroéthylène |
Preferred (foundation metadata concept) |
| 1,25-dihydroxy-vitamine D |
Acceptable (foundation metadata concept) |
| 1,3-dichloro-2-propanol |
Preferred (foundation metadata concept) |
| 1,3-dichloro-2-propanol (substance) |
Preferred (foundation metadata concept) |
| 1-1-bis-(p-chlorophényl)-2-nitrobutane |
Preferred (foundation metadata concept) |
| 1-1-bis-(p-chlorophényl)-2-nitropropane |
Preferred (foundation metadata concept) |
| 1-1-dichloro-1-nitroéthane |
Preferred (foundation metadata concept) |
| 1-chloro-1-nitropropane |
Preferred (foundation metadata concept) |
| 1-chloro-1-nitropropane (substance) |
Preferred (foundation metadata concept) |
| 1-chloro-1-nitroéthane |
Preferred (foundation metadata concept) |
| 1/2 mouvement |
Preferred (foundation metadata concept) |
| 1/4 de mouvement |
Preferred (foundation metadata concept) |
| 10 microgrammes de polysaccharides contre l'Haemophilus influenzae et 24 microgrammes d'anatoxine tétanique |
Preferred (foundation metadata concept) |
| 10 µg/0,5 ml du vaccin contre l'hépatite B recombinant |
Preferred (foundation metadata concept) |
| 10^2 |
Preferred (foundation metadata concept) |
| 10^3 |
Preferred (foundation metadata concept) |
| 10^4 |
Preferred (foundation metadata concept) |
| 10^5 |
Preferred (foundation metadata concept) |
| 10^6 |
Preferred (foundation metadata concept) |
| 10^7 |
Preferred (foundation metadata concept) |
| 10^e^ au 25^e^ centile |
Preferred (foundation metadata concept) |
| 10e étage |
Acceptable (foundation metadata concept) |
| 11-désoxycorticostérone |
Acceptable (foundation metadata concept) |
| 11e étage et étages supérieurs |
Acceptable (foundation metadata concept) |
| 12 heures |
Preferred (foundation metadata concept) |
| 123i-iode |
Preferred (foundation metadata concept) |
| 123i-iode iobenguane |
Preferred (foundation metadata concept) |
| 153sm-samarium lexidronam |
Acceptable (foundation metadata concept) |
| 16 x 16 |
Preferred (foundation metadata concept) |
| 16 x 22 |
Preferred (foundation metadata concept) |
| 17 x 22 |
Preferred (foundation metadata concept) |
| 17 x 25 |
Preferred (foundation metadata concept) |
| 18 x 22 |
Preferred (foundation metadata concept) |
| 18 x 25 |
Preferred (foundation metadata concept) |
| 18f-florbétabène |
Preferred (foundation metadata concept) |
| 18f-fluorodopa |
Preferred (foundation metadata concept) |
| 1:03 |
Preferred (foundation metadata concept) |
| 1:06 |
Preferred (foundation metadata concept) |
| 1:1,5 |
Preferred (foundation metadata concept) |
| 1:9 |
Preferred (foundation metadata concept) |
| 1er étage |
Acceptable (foundation metadata concept) |
| 2 heures |
Preferred (foundation metadata concept) |
| 2,3-époxy-1-propanol |
Preferred (foundation metadata concept) |
| 2,4-diisocyanate de toluène |
Preferred (foundation metadata concept) |
| 2,4-toluènediamine |
Preferred (foundation metadata concept) |
| 2,6-toluènediamine |
Preferred (foundation metadata concept) |
| 2-acétylaminofluorine |
Preferred (foundation metadata concept) |
| 2-amino-5-nitrothiazole |
Preferred (foundation metadata concept) |
| 2-amino-5-nitrothiazole (substance) |
Preferred (foundation metadata concept) |
| 2-bromo-4-phénylphénol |
Preferred (foundation metadata concept) |
| 2-chloro-4-nitrobenzamide |
Preferred (foundation metadata concept) |
| 2-chloroéthanol |
Preferred (foundation metadata concept) |
| 2-hydroxy-2,2-bis-(4-chlorophényl)éthyl acétate |
Preferred (foundation metadata concept) |
| 2-méthoxy-p-crésol |
Preferred (foundation metadata concept) |
| 2-méthylbutyrylglycinurie |
Preferred (foundation metadata concept) |
| 2-éthylhexyl-2-cyano-3,3-diphénylacrylate |
Preferred (foundation metadata concept) |
| 21 x 25 |
Preferred (foundation metadata concept) |
| 21-hydroxyprogestérone |
Acceptable (foundation metadata concept) |
| 24 heures |
Preferred (foundation metadata concept) |
| 25^e^ au 50^e^ centile |
Preferred (foundation metadata concept) |
| 2e étage |
Acceptable (foundation metadata concept) |
| 3,4-diaminopyridine |
Preferred (foundation metadata concept) |
| 3-3,dichlorobenzidine |
Preferred (foundation metadata concept) |
| 3-alpha-allo-tétrahydrocortisol |
Preferred (foundation metadata concept) |
| 3-méthoxyaniline |
Preferred (foundation metadata concept) |
| 3-phényl-salicylate de cuivre |
Preferred (foundation metadata concept) |
| 3/4 de mouvement |
Preferred (foundation metadata concept) |
| 30 mm |
Preferred (foundation metadata concept) |
| 3^e^ au 10^e^ centile |
Preferred (foundation metadata concept) |
| 3e étage |
Acceptable (foundation metadata concept) |
| 4 heures |
Preferred (foundation metadata concept) |